898 related articles for article (PubMed ID: 28465216)
21. Targeted therapies for ROS1-rearranged non-small cell lung cancer.
Patil T; Simons E; Mushtaq R; Pacheco JM; Doebele RC; Bowles DW
Drugs Today (Barc); 2019 Oct; 55(10):641-652. PubMed ID: 31720561
[TBL] [Abstract][Full Text] [Related]
22. Mouse models for ROS1-fusion-positive lung cancers and their application to the analysis of multikinase inhibitor efficiency.
Inoue M; Toki H; Matsui J; Togashi Y; Dobashi A; Fukumura R; Gondo Y; Minowa O; Tanaka N; Mori S; Takeuchi K; Noda T
Carcinogenesis; 2016 May; 37(5):452-60. PubMed ID: 26964870
[TBL] [Abstract][Full Text] [Related]
23. Efficacy of Crizotinib among Different Types of ROS1 Fusion Partners in Patients with ROS1-Rearranged Non-Small Cell Lung Cancer.
Li Z; Shen L; Ding D; Huang J; Zhang J; Chen Z; Lu S
J Thorac Oncol; 2018 Jul; 13(7):987-995. PubMed ID: 29704675
[TBL] [Abstract][Full Text] [Related]
24. Properties of FDA-approved small molecule protein kinase inhibitors: A 2020 update.
Roskoski R
Pharmacol Res; 2020 Feb; 152():104609. PubMed ID: 31862477
[TBL] [Abstract][Full Text] [Related]
25. Resistance Profile and Structural Modeling of Next-Generation ROS1 Tyrosine Kinase Inhibitors.
Keddy C; Shinde P; Jones K; Kaech S; Somwar R; Shinde U; Davare MA
Mol Cancer Ther; 2022 Feb; 21(2):336-346. PubMed ID: 34907086
[TBL] [Abstract][Full Text] [Related]
26. Molecular Changes Associated with Acquired Resistance to Crizotinib in ROS1-Rearranged Non-Small Cell Lung Cancer.
Song A; Kim TM; Kim DW; Kim S; Keam B; Lee SH; Heo DS
Clin Cancer Res; 2015 May; 21(10):2379-87. PubMed ID: 25688157
[TBL] [Abstract][Full Text] [Related]
27. CD74-ROS1 fusion transcripts in resected non-small cell lung carcinoma.
Matsuura S; Shinmura K; Kamo T; Igarashi H; Maruyama K; Tajima M; Ogawa H; Tanahashi M; Niwa H; Funai K; Kohno T; Suda T; Sugimura H
Oncol Rep; 2013 Oct; 30(4):1675-80. PubMed ID: 23877438
[TBL] [Abstract][Full Text] [Related]
28. Identifying and targeting ROS1 gene fusions in non-small cell lung cancer.
Davies KD; Le AT; Theodoro MF; Skokan MC; Aisner DL; Berge EM; Terracciano LM; Cappuzzo F; Incarbone M; Roncalli M; Alloisio M; Santoro A; Camidge DR; Varella-Garcia M; Doebele RC
Clin Cancer Res; 2012 Sep; 18(17):4570-9. PubMed ID: 22919003
[TBL] [Abstract][Full Text] [Related]
29. TPD52L1-ROS1, a new ROS1 fusion variant in lung adenosquamous cell carcinoma identified by comprehensive genomic profiling.
Zhu VW; Upadhyay D; Schrock AB; Gowen K; Ali SM; Ou SH
Lung Cancer; 2016 Jul; 97():48-50. PubMed ID: 27237027
[TBL] [Abstract][Full Text] [Related]
30. Identification of Existing Drugs That Effectively Target NTRK1 and ROS1 Rearrangements in Lung Cancer.
Chong CR; Bahcall M; Capelletti M; Kosaka T; Ercan D; Sim T; Sholl LM; Nishino M; Johnson BE; Gray NS; Jänne PA
Clin Cancer Res; 2017 Jan; 23(1):204-213. PubMed ID: 27370605
[TBL] [Abstract][Full Text] [Related]
31. Resistance to ROS1 inhibition mediated by EGFR pathway activation in non-small cell lung cancer.
Davies KD; Mahale S; Astling DP; Aisner DL; Le AT; Hinz TK; Vaishnavi A; Bunn PA; Heasley LE; Tan AC; Camidge DR; Varella-Garcia M; Doebele RC
PLoS One; 2013; 8(12):e82236. PubMed ID: 24349229
[TBL] [Abstract][Full Text] [Related]
32. Targeting ROS1 with anaplastic lymphoma kinase inhibitors: a promising therapeutic strategy for a newly defined molecular subset of non-small-cell lung cancer.
Chin LP; Soo RA; Soong R; Ou SH
J Thorac Oncol; 2012 Nov; 7(11):1625-30. PubMed ID: 23070242
[TBL] [Abstract][Full Text] [Related]
33. Crizotinib in the management of advanced-stage non-small-cell lung cancer.
Loong HH; Mok K; Leung LK; Mok TS
Future Oncol; 2015; 11(5):735-45. PubMed ID: 25757678
[TBL] [Abstract][Full Text] [Related]
34. ALK and ROS1 as targeted therapy paradigms and clinical implications to overcome crizotinib resistance.
Ye M; Zhang X; Li N; Zhang Y; Jing P; Chang N; Wu J; Ren X; Zhang J
Oncotarget; 2016 Mar; 7(11):12289-304. PubMed ID: 26802023
[TBL] [Abstract][Full Text] [Related]
35. P-glycoprotein Mediates Ceritinib Resistance in Anaplastic Lymphoma Kinase-rearranged Non-small Cell Lung Cancer.
Katayama R; Sakashita T; Yanagitani N; Ninomiya H; Horiike A; Friboulet L; Gainor JF; Motoi N; Dobashi A; Sakata S; Tambo Y; Kitazono S; Sato S; Koike S; John Iafrate A; Mino-Kenudson M; Ishikawa Y; Shaw AT; Engelman JA; Takeuchi K; Nishio M; Fujita N
EBioMedicine; 2016 Jan; 3():54-66. PubMed ID: 26870817
[TBL] [Abstract][Full Text] [Related]
36. Matching-adjusted indirect comparison: entrectinib versus crizotinib in
Chu P; Antoniou M; Bhutani MK; Aziez A; Daigl M
J Comp Eff Res; 2020 Aug; 9(12):861-876. PubMed ID: 32648475
[No Abstract] [Full Text] [Related]
37. Alectinib shows potent antitumor activity against RET-rearranged non-small cell lung cancer.
Kodama T; Tsukaguchi T; Satoh Y; Yoshida M; Watanabe Y; Kondoh O; Sakamoto H
Mol Cancer Ther; 2014 Dec; 13(12):2910-8. PubMed ID: 25349307
[TBL] [Abstract][Full Text] [Related]
38. A historical overview of protein kinases and their targeted small molecule inhibitors.
Roskoski R
Pharmacol Res; 2015 Oct; 100():1-23. PubMed ID: 26207888
[TBL] [Abstract][Full Text] [Related]
39. Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1).
Drilon A; Siena S; Ou SI; Patel M; Ahn MJ; Lee J; Bauer TM; Farago AF; Wheler JJ; Liu SV; Doebele R; Giannetta L; Cerea G; Marrapese G; Schirru M; Amatu A; Bencardino K; Palmeri L; Sartore-Bianchi A; Vanzulli A; Cresta S; Damian S; Duca M; Ardini E; Li G; Christiansen J; Kowalski K; Johnson AD; Patel R; Luo D; Chow-Maneval E; Hornby Z; Multani PS; Shaw AT; De Braud FG
Cancer Discov; 2017 Apr; 7(4):400-409. PubMed ID: 28183697
[TBL] [Abstract][Full Text] [Related]
40. ROS1-ADGRG6: a case report of a novel ROS1 oncogenic fusion variant in lung adenocarcinoma and the response to crizotinib.
Xu S; Wang W; Xu C; Li X; Ye J; Zhu Y; Ge T
BMC Cancer; 2019 Aug; 19(1):769. PubMed ID: 31382924
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
